These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 9590413

  • 1. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
    Cloud ML, Enas N, Humphries TJ, Bassion S.
    Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
    [Abstract] [Full Text] [Related]

  • 2. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD, Markham A.
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of rabeprazole once daily for acid-related disorders.
    Lanza F, Bardhan KD, Perdomo C, Niecestro R, Barth J.
    Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
    [Abstract] [Full Text] [Related]

  • 4. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI, Goa KL.
    Drugs; 2001 Mar; 61(15):2327-56. PubMed ID: 11772142
    [Abstract] [Full Text] [Related]

  • 5. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.
    Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
    Stack WA, Knifton A, Thirlwell D, Cockayne A, Jenkins D, Hawkey CJ, Atherton JC.
    Am J Gastroenterol; 1998 Oct; 93(10):1909-13. PubMed ID: 9772054
    [Abstract] [Full Text] [Related]

  • 7. [Comparative study of proton pump inhibitors].
    Herszényi L, Tulassay Z.
    Orv Hetil; 2001 Sep 09; 142(36):1953-61. PubMed ID: 11680100
    [Abstract] [Full Text] [Related]

  • 8. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A, Breiter J, Perdomo C, Barth J.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):193-202. PubMed ID: 16091056
    [Abstract] [Full Text] [Related]

  • 9. [Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].
    de Freitas JA, Lima LM, Ranieri JL, Olivieri JC, Fragoso HJ, Chinzon D.
    Arq Gastroenterol; 2002 Aug 01; 39(1):60-5. PubMed ID: 12184168
    [Abstract] [Full Text] [Related]

  • 10. Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans.
    Celinski K, Konturek PC, Konturek SJ, Slomka M, Cichoz-Lach H, Brzozowski T, Bielanski W.
    J Physiol Pharmacol; 2011 Oct 01; 62(5):521-6. PubMed ID: 22204799
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
    Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morocutti A, Miller N, Bardhan KD, European Rabeprazole Study Group.
    Aliment Pharmacol Ther; 2003 Feb 01; 17(3):343-51. PubMed ID: 12562446
    [Abstract] [Full Text] [Related]

  • 12. [Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
    Dtsch Med Wochenschr; 1998 Nov 20; 123(47 Suppl):1-4. PubMed ID: 9856116
    [No Abstract] [Full Text] [Related]

  • 13. [Pharma-clinics medication of the month. Rabeprazole (Pariet)].
    Louis E.
    Rev Med Liege; 2002 Jan 20; 57(1):53-6. PubMed ID: 11899500
    [Abstract] [Full Text] [Related]

  • 14. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ, Salas M, Ward A.
    Clin Ther; 2001 Jul 20; 23(7):998-1017. PubMed ID: 11519776
    [Abstract] [Full Text] [Related]

  • 15. The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
    Johnson D, Perdomo C, Barth J, Jokubaitis L.
    Eur J Gastroenterol Hepatol; 2000 Jul 20; 12(7):799-806. PubMed ID: 10929909
    [Abstract] [Full Text] [Related]

  • 16. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
    Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J.
    Am J Gastroenterol; 2000 Nov 20; 95(11):3081-8. PubMed ID: 11095321
    [Abstract] [Full Text] [Related]

  • 17. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
    Wang HH, Chou JW, Liao KF, Lin ZY, Lai HC, Hsu CH, Chen CB.
    World J Gastroenterol; 2005 Mar 21; 11(11):1680-4. PubMed ID: 15786549
    [Abstract] [Full Text] [Related]

  • 18. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
    Bardou M.
    Rev Prat; 2001 Apr 15; 51(7):789-95. PubMed ID: 11387678
    [No Abstract] [Full Text] [Related]

  • 19. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C.
    Clin Ther; 1993 Apr 15; 15 Suppl B():14-21. PubMed ID: 7911399
    [Abstract] [Full Text] [Related]

  • 20. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.
    Sloan S.
    Am J Gastroenterol; 2003 Mar 15; 98(3 Suppl):S49-55. PubMed ID: 12644031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.